Incyte (INCY) Long-Term Investments (2014 - 2026)
Incyte's (INCY) quarterly Long-Term Investments came in at $104.4 million in Q2 2026, up 684.1% YoY from $13.3 million in Q2 2025, and up 91.25% on a QoQ basis from $54.6 million in Q1 2026.
Incyte (INCY) Long-Term Investments (2014 - 2026) Analysis & Trends
Incyte (INCY) has 13 years of Long-Term Investments data on file, last reported at $104.4 million in Q2 2026.
- Quarterly Long-Term Investments rose 684.1% year-over-year to $104.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $104.4 million (up 684.1% YoY) and the FY2025 annual result came in at $48.0 million, up 155.08% from the prior year.
- Long-Term Investments climbed to $104.4 million in Q2 2026, from $54.6 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $287.7 million in Q1 2024 to a low of $13.3 million in Q2 2025.
- A 5-year average of $103.9 million and a median of $116.4 million in 2023 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2025 — Long-Term Investments slumped 93.93% — and 2026, when it surged 684.1%.
- Tracing INCY's Long-Term Investments over 5 years: stood at $133.7 million in 2022, then surged by 40.43% to $187.7 million in 2023, then slumped by 89.98% to $18.8 million in 2024, then surged by 155.08% to $48.0 million in 2025, then surged by 117.51% to $104.4 million in 2026.
- The last three Long-Term Investments figures came in at $104.4 million (Q2 2026), $54.6 million (Q1 2026), and $48.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 104.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.39 Mn |
| Mar 31, 2026 | 54.58 Mn |
| Dec 31, 2025 | 47.99 Mn |
| Sep 30, 2025 | 21.87 Mn |
| Jun 30, 2025 | 13.31 Mn |
| Mar 31, 2025 | 17.46 Mn |
| Dec 31, 2024 | 18.81 Mn |
| Sep 30, 2024 | 27.57 Mn |
| Jun 30, 2024 | 29.67 Mn |
| Mar 31, 2024 | 287.66 Mn |
| Dec 31, 2023 | 187.72 Mn |
| Sep 30, 2023 | 153.66 Mn |
| Jun 30, 2023 | 170.32 Mn |
| Mar 31, 2023 | 128.31 Mn |
| Dec 31, 2022 | 133.68 Mn |
| Sep 30, 2022 | 149.12 Mn |
| Jun 30, 2022 | 149.78 Mn |
| Mar 31, 2022 | 174.68 Mn |
| Dec 31, 2021 | 221.27 Mn |
| Sep 30, 2021 | 192.10 Mn |